[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.33 número3
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.33 número3" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.33 número3".
Rev. Bras. Hematol. Hemoter. vol.33 número3
... great scientific power led by China and including Brazil and also throws light on the growing scientific production of countries that are not normally mentioned such as Iran, Turkey and [r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.33 número3
... A cross-sectional, descriptive study was performed of 20 male and 25 female adult patients treated with HU for a period of 3 - 6 months (n = 12) or untreated (n = 33) as a follow-up activity at the outpatient ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.33 número3
... 18. Lourençon AF, Martinez EZ, Mazucheli J, Ferreira O. Modelos de sobrevivência de longa duração aplicados ao estudo do comporta- mento do doador de sangue voluntário. Rev Mat Estat [Internet]. 2007 [cited 2010 ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número3
... A number of attempts were made by the Brazilian Ministry of Health to implant this program however, it was not successful due to the low acceptance of ferrous sulfate by pregnant women [r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número3
... recommendable to adopt some measures in order to succeed in minimizing the adverse events and improve adherence to oral iron supplementation treatment, such as splitting the recommended [r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.33 número3
... homozygosis for alpha thalassemia (3.7 kb deletion) with sickle cell anemia is a factor that modulates the clinical variability and hematological severity, demonstrating a diversity of [r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número3
... 6. Souza AI, Batista Filho M, Bresani CC, Ferreira LO, Figueiroa JN. Adherence and s i d e e f f e c t s o f t h r e e f e r r o u s s u l f a t e treatment regimens on anemic pregnant women in clinical trials. Cad Saude ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.33 número3
... The authors believe that with an incidence of 4.3 reactions per 1000 transfusions the methodology described guarantees transfusion safety, making prompt medical care possible while provi[r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.33 número3
... MUD transplants, on the other hand, are limited by the fact that a matched donor can be identified for only 50% to 60% of patients who need them and the donor search and acquisition of an unrelated donor hematopoietic ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número3
... Findings from our research group studying genetic factors involved in γ -globin gene regulation in adults without anemia in the northwestern region of São Paulo State showed that high H[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.33 número3
... 59. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin- associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2006;(2):CD002827. 60. Hadden RDM, Nobile-Orazio ... See full document
10
Rev. Bras. Hematol. Hemoter. vol.33 número3
... The NKG2D receptor in the natural killer cells recognizes the transmembrane proteins related to major histocompatibility complex class I chain-related genes A and B (MICA and MICB), and [r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número3
... Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase – the importance of a major molecular response1. Medical Clinic, Universidade[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número3
... Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Chang H, Brandwein J, Yi QL[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número3
... Thus, this work aimed at investigating the effects of chronic stress on cells of the hematopoietic system including leukocytes, on the phagocytosis rate of monocytes and on the NO levels[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.33 número3
... of the maintenance phase in weeks; 3) duration of interruption of chemotherapy during the maintenance phase: percentage of days on which the patient did not receive 6-MP and MTX in relat[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número3
... 1. Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S, et al. H. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número3
... 3. Teixeira Neto PF, Gonçalves RP, Elias DBD, Araújo CP, Magalhães HIF. Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará-Brazil. Rev ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número3
... 10. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.33 número3
... The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia.. Hematology and Oncology Department, Faculdade de Medicina de Ribeirão Preto[r] ... See full document
2
temas relacionados